Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, January 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 208 articles:
HTML format


 

Single Articles

  1. HUANG ZM, Wang H, Ji ZG
    CircRNA-100284 activates aurora kinase B by inducing methylation of HSP70 via microRNA-217 to promote proliferation of bladder cancer cells.
    J Cancer Res Clin Oncol. 2021 Jan 1. pii: 10.1007/s00432-020-03468.
    PubMed    
    Abstract available

  2. HASHEM A, Mosbah A, El-Tabey NA, Laymon M, et al
    Holmium Laser En-bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle-invasive Bladder Cancer: A Randomized Clinical Trial.
    Eur Urol Focus. 2020 Dec 29. pii: S2405-4569(20)30303.
    PubMed    
    Abstract available

  3. SU Y, Feng W, Shi J, Chen L, et al
    Correction to: circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-beta2/smad3 pathway.
    Mol Cancer. 2021;20:1.
    PubMed    


  4. ZENG J, Zhang G, Chen C, Li K, et al
    Alterations in Urobiome in Patients With Bladder Cancer and Implications for Clinical Outcome: A Single-Institution Study.
    Front Cell Infect Microbiol. 2020;10:555508.
    PubMed    
    Abstract available

  5. HAFEEZ S, Webster A, Hansen VN, McNair HA, et al
    Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance.
    BMJ Open. 2020;10:e041005.
    PubMed    
    Abstract available

  6. ZHOU Q, Ding W, Qian Z, Jiang G, et al
    Chronic Unpredictable Mild Stress Accelerates the Growth of Bladder Cancer in a Xenograft Mouse Model.
    Psychol Res Behav Manag. 2020;13:1289-1297.
    PubMed    
    Abstract available

  7. MIRZAEI S, Gholami MH, Mahabady MK, Nabavi N, et al
    Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation.
    Biomed Pharmacother. 2021;133:111077.
    PubMed    
    Abstract available

  8. GILL J, Prasad V
    Pembrolizumab for Non-Muscle-Invasive Bladder Cancer-A Costly Therapy in Search of Evidence.
    JAMA Oncol. 2020 Dec 30. pii: 2774444. doi: 10.1001/jamaoncol.2020.6142.
    PubMed    


  9. CHANG Y, Jin H, Li H, Ma J, et al
    MiRNA-516a promotes bladder cancer metastasis by inhibiting MMP9 protein degradation via the AKT/FOXO3A/SMURF1 axis.
    Clin Transl Med. 2020;10:e263.
    PubMed    
    Abstract available

  10. HUANG HM, Li HX
    Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer.
    Cancer Commun (Lond). 2020 Dec 30. doi: 10.1002/cac2.12129.
    PubMed    
    Abstract available

  11. YU H, Yang X, Tang J, Si S, et al
    ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2alpha-Mediated Glycolysis.
    Mol Ther Nucleic Acids. 2020;23:27-41.
    PubMed    
    Abstract available

  12. WU CT, Huang YC, Chen WC, Chen MF, et al
    The Significance of Neutrophil-to-Lymphocyte Ratio and Combined Chemoradiotherapy in Patients Undergoing Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
    Cancer Manag Res. 2020;12:13125-13135.
    PubMed    
    Abstract available

  13. WOLFS JRE, Hermans TJN, Koldewijn EL, van de Kerkhof D, et al
    Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Urol Oncol. 2020 Dec 26. pii: S1078-1439(20)30583.
    PubMed    
    Abstract available

  14. XU C, Liu M, Jia D, Tao T, et al
    lncRNA TINCR SNPs and Expression Levels Are Associated with Bladder Cancer Susceptibility.
    Genet Test Mol Biomarkers. 2020 Dec 28. doi: 10.1089/gtmb.2020.0178.
    PubMed    
    Abstract available

  15. SIMSEKOGLU MF, Kaleler I, Onal B, Demirdag C, et al
    Do Urinary Mast Cell Mediators Predict Immune Response to BCG in Patients with Primary High-Grade Non-Muscle Invasive Bladder Cancer?
    Int J Clin Pract. 2020 Dec 23:e13959. doi: 10.1111/ijcp.13959.
    PubMed    
    Abstract available

  16. WITJES JA
    Follow-up in non-muscle invasive bladder cancer: facts and future.
    World J Urol. 2020 Dec 26. pii: 10.1007/s00345-020-03569.
    PubMed    
    Abstract available

  17. CHI Q, Xu H, Song D, Wang Z, et al
    alpha-E-Catenin (CTNNA1) Inhibits Cell Proliferation, Invasion and EMT of Bladder Cancer.
    Cancer Manag Res. 2020;12:12747-12758.
    PubMed    
    Abstract available

  18. SIRAJ F, Dulal J, Sharma S, Gupta P, et al
    Benign Mimickers of Urinary Bladder Cancer: a Case Series.
    Indian J Surg Oncol. 2020;11.
    PubMed    
    Abstract available

  19. LI SL, Li ZF, Cao QW, Wang WZ, et al
    SLC12A8 plays a key role in bladder cancer progression and EMT.
    Open Med (Wars). 2020;16:58-67.
    PubMed    
    Abstract available

  20. BRAHIM D, Mechergui N, Ben Said H, Cherif D, et al
    Peritoneal mesothelioma associated with bladder cancer and occupational exposure to asbestos: A case report.
    Clin Case Rep. 2020;8:3529-3532.
    PubMed    
    Abstract available

  21. ZHUANG C, Liu Y, Fu S, Yuan C, et al
    Silencing of lncRNA MIR497HG via CRISPR/Cas13d Induces Bladder Cancer Progression Through Promoting the Crosstalk Between Hippo/Yap and TGF-beta/Smad Signaling.
    Front Mol Biosci. 2020;7:616768.
    PubMed    
    Abstract available

  22. LI T, Yu Y, Shi H, Cao Y, et al
    Magnesium in Combinatorial With Valproic Acid Suppressed the Proliferation and Migration of Human Bladder Cancer Cells.
    Front Oncol. 2020;10:589112.
    PubMed    
    Abstract available

  23. LUCAS M, Jansen I, van Leeuwen TG, Oddens JR, et al
    Deep Learning-based Recurrence Prediction in Patients with Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2020 Dec 22. pii: S2405-4569(20)30310.
    PubMed    
    Abstract available

  24. HOFFMAN-CENSITS J, Choi W, Bivalacqua TJ, Pierorazio P, et al
    Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience.
    Clin Genitourin Cancer. 2020 Nov 12. pii: S1558-7673(20)30251.
    PubMed    


  25. LYU Q, Lin A, Cao M, Xu A, et al
    Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
    Cancer Control. 2020;27:1073274820976665.
    PubMed    
    Abstract available

  26. KUMAR A, Gupta R, Mathur N, Iyer VK, et al
    Microarray based gene expression profiling of advanced gall bladder cancer.
    Exp Oncol. 2020;42:277-284.
    PubMed    
    Abstract available

  27. GIRARD A, Vila Reyes H, Dercle L, Rouanne M, et al
    "Future role of [18F]-FDG PET/CT in patients with bladder cancer in the new era of neoadjuvant immunotherapy?"
    Urol Oncol. 2020 Dec 19. pii: S1078-1439(20)30632.
    PubMed    


  28. ECKE TH, Otto T, Le Calvez-Kelm F
    Evaluating the Utility of Combined Bladder Cancer Biomarkers, the Molecular Prognostication of Tumor Subtypes, or What Else Is Needed to Illuminate Our Vision?
    Int J Mol Sci. 2020;21.
    PubMed    
    Abstract available

  29. SUZUKI S, Cohen SM, Arnold LL, Pennington KL, et al
    Cell proliferation of rat bladder urothelium induced by nicotine is suppressed by the NADPH oxidase inhibitor, apocynin.
    Toxicol Lett. 2021;336:32-38.
    PubMed    
    Abstract available

  30. YANAI Y, Kosaka T, Nakamura K, Aimono E, et al
    CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression.
    Cancer Sci. 2020;111:4652-4655.
    PubMed    
    Abstract available

  31. FUKAI K, Kojimahara N, Hoshi K, Toyota A, et al
    Combined effects of occupational exposure to hazardous operations and lifestyle-related factors on cancer incidence.
    Cancer Sci. 2020;111:4581-4593.
    PubMed    
    Abstract available

  32. SMITH ME, Farahani SJ, Chao T, Palmer M, et al
    PD-L1 Positivity Associated With Presence of Tertiary Lymphoid Structures and High-Stage Disease in Upper Tract Urothelial Carcinoma.
    Am J Clin Pathol. 2020;154:802-810.
    PubMed    
    Abstract available

  33. ZRIBI A, Nasr SB, Msakni I, Karrit S, et al
    Urothelial bladder carcinoma in childhood: a case report.
    Pan Afr Med J. 2020;36:91.
    PubMed    
    Abstract available

  34. KADOURI Y, Hachem F, Lakssir J, Sayegh H, et al
    [Primitive adenocarcinoma of the bladder: about 6 cases].
    Pan Afr Med J. 2020;36:61.
    PubMed    
    Abstract available

  35. TAARNHOJ GA, Lindberg H, Dohn LH, Omland LH, et al
    Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy - a feasibility study.
    Health Qual Life Outcomes. 2020;18:225.
    PubMed    
    Abstract available

  36. NASROLLAHI H, Ariafar A, Ahmed F, Mokhtari M, et al
    Isolated schwannoma of the urinary bladder: a case report and review of the literature.
    Pan Afr Med J. 2020;35:108.
    PubMed    
    Abstract available

  37. KIMURA N, Tsuchiya A, Oda C, Kimura A, et al
    Portal Vein Thrombosis Associated with Trousseau Syndrome due to Urinary Bladder Squamous Cell Carcinoma in a Liver Cirrhosis Patient.
    Intern Med. 2020 May 23. doi: 10.2169/internalmedicine.4112.
    PubMed    
    Abstract available

  38. PALUMBO C, Knipper S, Pecoraro A, Rosiello G, et al
    Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients.
    Eur J Surg Oncol. 2020;46:1347-1352.
    PubMed    
    Abstract available

  39. AREFI SMA, Tsvirkun D, Verdier C, Feng JJ, et al
    A biomechanical model for the transendothelial migration of cancer cells.
    Phys Biol. 2020;17:036004.
    PubMed    
    Abstract available

  40. WANG B, Huang H, Yang M, Yang W, et al
    Microlocalization and clinical significance of stabilin-1(+) macrophages in treatment-naive patients with urothelial carcinoma of the bladder.
    World J Urol. 2020;38:709-716.
    PubMed    
    Abstract available

  41. HURLE R, Casale P, Lazzeri M, Paciotti M, et al
    En bloc re-resection of high-risk NMIBC after en bloc resection: results of a multicenter observational study.
    World J Urol. 2020;38:703-708.
    PubMed    
    Abstract available

  42. STROOBANTS S, Bijnens E, Herbots L
    A mass in the right ventricle.
    Acta Cardiol. 2020;75:167-169.
    PubMed    


  43. RHEA LP, Mendez-Marti S, Kim D, Aragon-Ching JB, et al
    Role of immunotherapy in bladder cancer.
    Cancer Treat Res Commun. 2020;26:100296.
    PubMed    
    Abstract available

  44. MARCQ G, Souhami L, Cury FL, Salimi A, et al
    Phase I Trial of Atezolizumab plus Trimodal Therapy in Patients with localized Muscle-Invasive Bladder Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Jan 6. pii: S0360-3016(20)34729.
    PubMed    
    Abstract available

  45. VANDEKERKHOVE G, Lavoie JM, Annala M, Murtha AJ, et al
    Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
    Nat Commun. 2021;12:184.
    PubMed    
    Abstract available

  46. KOTOLLOSHI R, Holzer M, Gajda M, Grimm MO, et al
    SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells.
    Cells. 2021;10.
    PubMed    
    Abstract available

  47. GRAHAM CH, Pare JF, Cotechini T, Hopman W, et al
    Innate immune memory is associated with increased disease-free survival in bladder cancer patients treated with bacillus Calmette-Guerin.
    Can Urol Assoc J. 2021 Jan 4. pii: cuaj.7066. doi: 10.5489/cuaj.7066.
    PubMed    
    Abstract available

  48. WANG X, Zhang R, Wu T, Shi Y, et al
    Successive treatment with naltrexone induces epithelial-mesenchymal transition and facilitates the malignant biological behaviors of bladder cancer cells.
    Acta Biochim Biophys Sin (Shanghai). 2021 Jan 7. pii: 6067264.
    PubMed    
    Abstract available

  49. YAN Y, Huang Z, Cai J, Tang P, et al
    Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Aging (Albany NY). 2020;12.
    PubMed    
    Abstract available

  50. ORESTA B, Pozzi C, Braga D, Hurle R, et al
    Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer.
    Sci Transl Med. 2021;13.
    PubMed    
    Abstract available

  51. SHAO Y, Hu X, Yang Z, Lia T, et al
    Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing.
    Cancer Cell Int. 2021;21:23.
    PubMed    
    Abstract available

  52. CHEN D, Cheng L, Cao H, Liu W, et al
    Role of microRNA-381 in bladder cancer growth and metastasis with the involvement of BMI1 and the Rho/ROCK axis.
    BMC Urol. 2021;21:5.
    PubMed    
    Abstract available

  53. XIU W, Luo J
    CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling.
    BMC Immunol. 2021;22:3.
    PubMed    
    Abstract available

  54. ZHAO M, Zhang M, Wang Y, Yang X, et al
    Prognostic Value of Preoperative Albumin-to-Alkaline Phosphatase Ratio in Patients with Muscle-Invasive Bladder Cancer After Radical Cystectomy.
    Onco Targets Ther. 2020;13:13265-13274.
    PubMed    
    Abstract available

  55. FERINI G, Cacciola A, Parisi S, Lillo S, et al
    Curative Radiotherapy in Elderly Patients With Muscle Invasive Bladder Cancer: The Prognostic Role of Sarcopenia.
    In Vivo. 2021;35:571-578.
    PubMed    
    Abstract available

  56. LIEVORE E, Runza L, Ghidini M, Galassi B, et al
    Micropapillary Bladder Cancer Metastatic to the Breast: A Case Report and Brief Literature Review.
    In Vivo. 2021;35:453-459.
    PubMed    
    Abstract available

  57. GOUTAS D, Tzortzis A, Gakiopoulou H, Vlachodimitropoulos D, et al
    Contemporary Molecular Classification of Urinary Bladder Cancer.
    In Vivo. 2021;35:75-80.
    PubMed    
    Abstract available

  58. CABAILLE M, Khalifa J, Tessier AM, Belhomme S, et al
    [A review of adaptive radiotherapy for bladder cancer].
    Cancer Radiother. 2021 Jan 2. pii: S1278-3218(20)30331.
    PubMed    
    Abstract available

  59. GANDI C, Vaccarella L, Bientinesi R, Racioppi M, et al
    Bladder cancer in the time of machine learning: Intelligent tools for diagnosis and management.
    Urologia. 2021 Jan 5:391560320987169. doi: 10.1177/0391560320987169.
    PubMed    
    Abstract available

  60. LOPEZ-BELTRAN A, Cimadamore A, Blanca A, Massari F, et al
    Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  61. TANG C, Wu Y, Wang X, Chen K, et al
    LncRNA MAFG-AS1 regulates miR-125b-5p/SphK1 axis to promote the proliferation, migration, and invasion of bladder cancer cells.
    Hum Cell. 2021 Jan 5. pii: 10.1007/s13577-020-00470.
    PubMed    
    Abstract available

  62. TAMALUNAS A, Schulz GB, Rodler S, Apfelbeck M, et al
    [Systemic treatment of bladder cancer].
    Urologe A. 2021 Jan 4. pii: 10.1007/s00120-020-01420.
    PubMed    
    Abstract available

  63. SMELSER WW, Randall JH, Caldwell J, Glavin K, et al
    Characterization of perioperative androgen profiles in men with bladder cancer undergoing radical cystectomy.
    Urol Oncol. 2021 Jan 1. pii: S1078-1439(20)30642.
    PubMed    
    Abstract available

  64. YANG X, Ye T, Liu H, Lv P, et al
    Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer.
    Mol Cancer. 2021;20:4.
    PubMed    
    Abstract available

  65. SAMAHA H, Samaha R, Sarkis J, Kattan J, et al
    Maintenance avelumab in metastatic bladder cancer as a step towards sequencing immunotherapy.
    Immunotherapy. 2021 Jan 5. doi: 10.2217/imt-2020-0261.
    PubMed    


  66. MATI Q, Qamar S, Ashraf S, Khokhar MA, et al
    Tissue Nuclear Matrix Protein Expression 22 in Various Grades and Stages of Bladder Cancer.
    J Coll Physicians Surg Pak. 2020;30:1321-1325.
    PubMed    
    Abstract available

  67. SILINA L, Maksut F, Bernard-Pierrot I, Radvanyi F, et al
    Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives.
    Cancers (Basel). 2020;13.
    PubMed    
    Abstract available

  68. SZARVAS T, Hoffmann MJ, Olah C, Szekely E, et al
    MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients.
    Diagnostics (Basel). 2020;11.
    PubMed    
    Abstract available

  69. STEPIEN A, Brudlo M, Stachura T, Marcinek P, et al
    Miliary pulmonary tuberculosis after the first dose of intravesical BCG instillation in a patient with high-grade bladder cancer.
    Adv Respir Med. 2020;88:628-629.
    PubMed    


  70. ZHENG Z, Mao S, Zhang W, Liu J, et al
    Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer.
    Front Oncol. 2020;10:542492.
    PubMed    
    Abstract available

  71. BI H, Yan Y, Wang D, Qin Z, et al
    Predictive value of preoperative lymphocyte-to-monocyte ratio on survival outcomes in bladder cancer patients after radical cystectomy.
    J Cancer. 2021;12:305-315.
    PubMed    
    Abstract available

  72. LI F, Xie W, Fang Y, Xie K, et al
    HnRNP-F promotes the proliferation of bladder cancer cells mediated by PI3K/AKT/FOXO1.
    J Cancer. 2021;12:281-291.
    PubMed    
    Abstract available

  73. KHAYAMZADEH M, Aliakbari F, Zolghadr Z, Emadeddin M, et al
    Five-Year Survival Rate of Bladder Cancer in Iran during 2001-2007.
    Iran J Pathol. 2021;16:69-74.
    PubMed    
    Abstract available

  74. JIANG A, Liu N, Bai S, Wang J, et al
    The Construction and Analysis of Tumor-Infiltrating Immune Cells and ceRNA Networks in Bladder Cancer.
    Front Genet. 2020;11:605767.
    PubMed    
    Abstract available

  75. WU X, Lv D, Cai C, Zhao Z, et al
    A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
    Front Immunol. 2020;11:590618.
    PubMed    
    Abstract available

  76. ZHENG X, Qiu S, Yang L, Wei Q, et al
    Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: An updated meta-analysis.
    Int J Med Sci. 2021;18:505-510.
    PubMed    
    Abstract available

  77. XIE R, Chen X, Chen Z, Huang M, et al
    Corrigendum to "Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM." [Canc. Lett. 449 (2019) 31-44].
    Cancer Lett. 2020 Dec 31. pii: S0304-3835(20)30687.
    PubMed    


  78. CHEN Z, Liu G, Liu G, Bolkov MA, et al
    Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.
    Hereditas. 2021;158:1.
    PubMed    
    Abstract available

  79. LENIS AT, Lec PM, Chamie K
    Urinary Diversion.
    JAMA. 2020;324:2222.
    PubMed    


  80. BANDINI M, Gibb EA, Gallina A, Raggi D, et al
    Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study().
    Ann Oncol. 2020;31:1755-1763.
    PubMed    
    Abstract available

  81. YEH BW, Yu LE, Li CC, Yang JC, et al
    The protoapigenone analog WYC0209 targets CD133+ cells: A potential adjuvant agent against cancer stem cells in urothelial cancer therapy.
    Toxicol Appl Pharmacol. 2020;402:115129.
    PubMed    
    Abstract available

  82. MUSSER ML, Viall AK, Phillips RL, Hostetter JM, et al
    Gene expression of prostaglandin EP4 receptor in three canine carcinomas.
    BMC Vet Res. 2020;16:213.
    PubMed    
    Abstract available

  83. OLKHOV-MITSEL E, Hodgson A, Liu SK, Vesprini D, et al
    Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
    J Clin Pathol. 2021;74:53-57.
    PubMed    
    Abstract available

  84. WYSOCKA M, Romanowska A, Gruba N, Michalska M, et al
    A Peptidomimetic Fluorescent Probe to Detect the Trypsin beta2 Subunit of the Human 20S Proteasome.
    Int J Mol Sci. 2020;21.
    PubMed    
    Abstract available

  85. XIANG Y, Zhang Q, Wei S, Huang C, et al
    Paeoniflorin: a monoterpene glycoside from plants of Paeoniaceae family with diverse anticancer activities.
    J Pharm Pharmacol. 2020;72:483-495.
    PubMed    
    Abstract available

  86. ROSKOSKI R JR
    The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Pharmacol Res. 2020;151:104567.
    PubMed    
    Abstract available

  87. CHEN YT, Ou Yang WT, Juang HH, Chen CL, et al
    Proteomic characterization of arsenic and cadmium exposure in bladder cells.
    Rapid Commun Mass Spectrom. 2020;34 Suppl 1:e8578.
    PubMed    
    Abstract available

  88. XUE M, Chen W, Li X
    Extracellular vesicle-transferred long noncoding RNAs in bladder cancer.
    Clin Chim Acta. 2021 Jan 12. pii: S0009-8981(21)00012.
    PubMed    
    Abstract available

  89. VAN VALENBERG FJP, Brummelhuis ISG, Lindner LH, Kuhnle F, et al
    DPPG2-Based Thermosensitive Liposomes with Encapsulated Doxorubicin Combined with Hyperthermia Lead to Higher Doxorubicin Concentrations in the Bladder Compared to Conventional Application in Pigs: A Rationale for the Treatment of Muscle-Invasive Blad
    Int J Nanomedicine. 2021;16:75-88.
    PubMed    
    Abstract available

  90. JENSEN BT, Lauridsen SV
    Commentary: Future Directions in Bladder Cancer Care.
    Semin Oncol Nurs. 2021 Jan 11:151117. doi: 10.1016/j.soncn.2020.151117.
    PubMed    


  91. NAIR SS, Weil R, Dovey Z, Davis A, et al
    The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
    Urol Clin North Am. 2020;47.
    PubMed    
    Abstract available

  92. STRUCK JP, Hupe MC, Heinisch A, Ozimek T, et al
    RLC score (R status, lymphovascular invasion, C-reactive protein) predicts survival following radical cystectomy for muscle-invasive bladder cancer.
    Aktuelle Urol. 2021 Jan 14. doi: 10.1055/a-1310-3583.
    PubMed    
    Abstract available

  93. MA X, Mao G, Chang R, Wang F, et al
    Down-regulation of Autophagy-Associated Protein Increased Acquired Radio-Resistance Bladder Cancer Cells Sensitivity to Taxol.
    Int J Radiat Biol. 2021 Jan 14:1-34. doi: 10.1080/09553002.2021.1872812.
    PubMed    
    Abstract available

  94. VOLLMER T, Schlickeiser S, Amini L, Schulenberg S, et al
    The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer.
    Sci Transl Med. 2021;13.
    PubMed    
    Abstract available

  95. GUAN H, Lu J, Qu M, Meng L, et al
    DNA methylation patterns of SOCS1 gene in peripheral blood identifies risk loci associated with Bladder cancer based on principal component analysis.
    Neoplasma. 2021 Jan 14. pii: 200928N1035. doi: 10.4149/neo_2020_200928N1035.
    PubMed    
    Abstract available

  96. FERRO M, Marchioni M, Lucarelli G, Dorin VM, et al
    Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study.
    Minerva Urol Nefrol. 2021 Jan 13. pii: S0393-2249.20.04076.
    PubMed    
    Abstract available

  97. ZANG Y, Li X, Cheng Y, Qi F, et al
    An overview of patients with urothelial bladder cancer over the past two decades: a Surveillance, Epidemiology, and End Results (SEER) study.
    Ann Transl Med. 2020;8:1587.
    PubMed    
    Abstract available

  98. DER STEEN-BANASIK EV, Oosterveld B, Smits G, Atema E, et al
    Perpetual role of brachytherapy in organ-sparing treatment for bladder cancer: a historical review.
    J Contemp Brachytherapy. 2020;12:618-628.
    PubMed    
    Abstract available

  99. HUSSEIN AA, Elsayed AS, Durrani M, Jing Z, et al
    Investigating the association between the urinary microbiome and bladder cancer: An exploratory study.
    Urol Oncol. 2021 Jan 9. pii: S1078-1439(20)30641.
    PubMed    
    Abstract available

  100. MCCAW ZR, Odisho AY, Chaparala H, Yin M, et al
    Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times.
    Urol Oncol. 2021 Jan 9. pii: S1078-1439(20)30640.
    PubMed    
    Abstract available

  101. JENSEN BT, Lauridsen SV
    Introduction: Bladder Cancer.
    Semin Oncol Nurs. 2021 Jan 9:151103. doi: 10.1016/j.soncn.2020.151103.
    PubMed    


  102. TAVARES-DA-SILVA E, Pereira E, Pires AS, Neves AR, et al
    Cold Atmospheric Plasma, a Novel Approach against Bladder Cancer, with Higher Sensitivity for the High-Grade Cell Line.
    Biology (Basel). 2021;10.
    PubMed    
    Abstract available

  103. MENG X, Hu H, Wang Y, Hu D, et al
    Application of bi-planar reduced field-of-view DWI (rFOV DWI) in the assessment of muscle-invasiveness of bladder cancer.
    Eur J Radiol. 2020;136:109486.
    PubMed    
    Abstract available

  104. LI Q, Cao B, Tan Q, Liu K, et al
    Prediction of muscle invasion of bladder cancer: A comparison between DKI and conventional DWI.
    Eur J Radiol. 2021;136:109522.
    PubMed    
    Abstract available

  105. STEENBERG CK, Bredberg A, Eiken R
    A man in his seventies with dyspnoea and ataxia after BCG instillation for bladder cancer.
    Tidsskr Nor Laegeforen. 2021;141.
    PubMed    


  106. JIANG DM, Gupta S, Kitchlu A, Meraz-Munoz A, et al
    Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.
    Nat Rev Urol. 2021 Jan 11. pii: 10.1038/s41585-020-00404.
    PubMed    
    Abstract available

  107. MAISCH P, Lunger L, Duwel C, Schmid SC, et al
    Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer.
    Urol Oncol. 2021 Jan 8. pii: S1078-1439(20)30629.
    PubMed    
    Abstract available

  108. GOLTZ HH, Major JE, Goffney J, Dunn MW, et al
    Collaboration Between Oncology Social Workers and Nurses: A Patient-Centered Interdisciplinary Model of Bladder Cancer Care.
    Semin Oncol Nurs. 2021 Jan 8:151114. doi: 10.1016/j.soncn.2020.151114.
    PubMed    
    Abstract available

  109. HANSEN TTD, Omland LH, von Heymann A, Johansen C, et al
    Development of Sarcopenia in Patients With Bladder Cancer: A Systematic Review.
    Semin Oncol Nurs. 2021 Jan 8:151108. doi: 10.1016/j.soncn.2020.151108.
    PubMed    
    Abstract available

  110. JENSEN BT
    Organization Factors in the ERAS Bladder Cancer Pathway: The Multifarious Role of the ERAS Nurse, Why and What Is Important?
    Semin Oncol Nurs. 2021 Jan 8:151106. doi: 10.1016/j.soncn.2020.151106.
    PubMed    
    Abstract available

  111. MCCONKEY RW, Dowling M
    Supportive Care Needs of Patients on Surveillance and Treatment for Non-Muscle-Invasive Bladder Cancer.
    Semin Oncol Nurs. 2021 Jan 8:151105. doi: 10.1016/j.soncn.2020.151105.
    PubMed    
    Abstract available

  112. SONG JH, Park J, Park SL, Hwang B, et al
    A Novel Cyclic Pentadepsipeptide, N-Methylsansalvamide, Suppresses Angiogenic Responses and Exhibits Antitumor Efficacy against Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  113. SANTOS LL, Santos J, Gouveia MJ, Bernardo C, et al
    Urogenital Schistosomiasis-History, Pathogenesis, and Bladder Cancer.
    J Clin Med. 2021;10.
    PubMed    
    Abstract available

  114. MOSTAFID H
    No 'one size fits all' approach in the management of high-risk non-muscle invasive bladder cancer.
    Scand J Urol. 2021 Jan 11:1-2. doi: 10.1080/21681805.2020.1866661.
    PubMed    


  115. WANG A, Jiang A, Gan X, Wang Z, et al
    EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR.
    Biomed Res Int. 2020;2020:6665974.
    PubMed    
    Abstract available

  116. LUO KW, Zhu XH, Zhao T, Zhong J, et al
    EGCG Enhanced the Anti-tumor Effect of Doxorubicine in Bladder Cancer via NF-kappaB/MDM2/p53 Pathway.
    Front Cell Dev Biol. 2020;8:606123.
    PubMed    
    Abstract available

  117. ZHENG H, Yang C, Tang J
    Cyclic RNA Circ_0000735 sponges miR-502-5p to promote bladder cancer cell proliferation and invasion and inhibit apoptosis.
    Int J Clin Exp Pathol. 2020;13:2994-3003.
    PubMed    
    Abstract available

  118. OU-YANG S, Liu JH, Wang QZ
    Upregulation of RAC3 in bladder cancer predicts adverse clinical outcome and increased tumor immune response.
    Int J Clin Exp Pathol. 2020;13:2937-2949.
    PubMed    
    Abstract available

  119. VAN RHIJN BWG, Hentschel AE, Brundl J, Comperat EM, et al
    Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.
    Eur Urol Oncol. 2021 Jan 8. pii: S2588-9311(20)30210.
    PubMed    
    Abstract available

  120. ELSHABRAWY A, Wang H, Satsangi A, Wheeler K, et al
    Correlates of refusal of radical cystectomy in patients with muscle-invasive bladder cancer.
    Urol Oncol. 2021 Jan 7. pii: S1078-1439(20)30610.
    PubMed    
    Abstract available

  121. MOHAMED NE, Leung TM, Kata HE, Shah QN, et al
    Identifying Distinct High Unmet-Need Phenotypes and Their Associated Bladder Cancer Patient Demographic, Clinical, Psychosocial, and Functional Characteristics: Results of Two Clustering Methods.
    Semin Oncol Nurs. 2021 Jan 7:151112. doi: 10.1016/j.soncn.2020.151112.
    PubMed    
    Abstract available

  122. SHAN G, Zhou X, Gu J, Zhou D, et al
    Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/beta-catenin pathway and upregulating PTEN.
    Cell Oncol (Dordr). 2021 Jan 10. pii: 10.1007/s13402-020-00500.
    PubMed    
    Abstract available

  123. CABAILLE M, Gaston R, Belhomme S, Giraud A, et al
    [Plan of the day adaptive radiotherapy for bladder cancer: Dosimetric and clinical results].
    Cancer Radiother. 2021 Jan 6. pii: S1278-3218(20)30347.
    PubMed    
    Abstract available

  124. DOHN LH, Omland LH, Stormoen DR, Pappot H, et al
    Status of Metastatic Bladder Cancer Treatment Illustrated by a Case.
    Semin Oncol Nurs. 2021 Jan 6:151113. doi: 10.1016/j.soncn.2020.151113.
    PubMed    
    Abstract available

  125. KADOURI Y, Ouskri S, Sayegh HE, Benslimane L, et al
    Sarcomatoid carcinoma of the urinary bladder: analysis of five cases and literature review.
    Pan Afr Med J. 2020;36:369.
    PubMed    
    Abstract available

  126. WU B, Pan C, Yao Z, Zhu X, et al
    A new ureteroileal anastomosis technique in modified ileal orthotopic bladder substitution after radical cystectomy.
    World J Surg Oncol. 2020;18:72.
    PubMed    
    Abstract available

  127. HSU YP, Yang HW, Li NS, Chen YT, et al
    Instrument-Free Detection of FXYD3 Using Vial-Based Immunosensor for Earlier and Faster Urothelial Carcinoma Diagnosis.
    ACS Sens. 2020;5:928-935.
    PubMed    
    Abstract available

  128. SIRAJ AK, Bu R, Iqbal K, Parvathareddy SK, et al
    Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
    Genomics. 2020;112:1746-1753.
    PubMed    
    Abstract available

  129. KIM SH
    Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor.
    Abdom Radiol (NY). 2020;45:491-498.
    PubMed    
    Abstract available

  130. SELF D, Ranasinghe W, Edirisinghe A, Ruthven S, et al
    Primary squamous cell carcinoma of the bladder presenting with colovesical and vesicocutaneous fistulae in a 29-year-old.
    ANZ J Surg. 2020;90:E34-E37.
    PubMed    


  131. AHMED MAH, Ali MH, Abbas HH, Elatrash GA, et al
    Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder.
    Pathol Oncol Res. 2020;26:411-418.
    PubMed    
    Abstract available

  132. MARVASO G, Nicosia L, Vinciguerra A, Borghetti P, et al
    The role of palliative radiotherapy in the management of elderly and frail patients with advanced bladder cancer: A survey by the AIRO uro-group.
    Med Oncol. 2021;38:14.
    PubMed    
    Abstract available

  133. FENG R, Li Z, Wang X, Ge G, et al
    Silenced lncRNA SNHG14 restrains the biological behaviors of bladder cancer cells via regulating microRNA-211-3p/ESM1 axis.
    Cancer Cell Int. 2021;21:67.
    PubMed    
    Abstract available

  134. LIU B, Pan S, Liu J, Kong C, et al
    Cancer-associated fibroblasts and the related Runt-related transcription factor 2 (RUNX2) promote bladder cancer progression.
    Gene. 2021 Jan 19:145451. doi: 10.1016/j.gene.2021.145451.
    PubMed    
    Abstract available

  135. HU X, Xiang L, He D, Zhu R, et al
    The long noncoding RNA KTN1-AS1 promotes bladder cancer tumorigenesis via KTN1 cis-activation and the consequent initiation of Rho GTPase-mediated signaling.
    Clin Sci (Lond). 2021 Jan 22. pii: 227665. doi: 10.1042/CS20200908.
    PubMed    
    Abstract available

  136. PYRGIDIS N, Lackner J, Schneidewind L, Sokolakis I, et al
    [Treatment of Ta and T1 intermediate or high risk bladder cancer with intravesical Bacillus Calmette-Guerin or mitomycin C].
    Urologe A. 2021 Jan 22. pii: 10.1007/s00120-021-01443.
    PubMed    


  137. TARANTINO G, Crocetto F, Di Vito C, Creta M, et al
    Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study.
    J Clin Med. 2021;10.
    PubMed    
    Abstract available

  138. BOHMER D, Grun A
    Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer : In response to: Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions published by Di Mar
    Curr Oncol Rep. 2021;23:18.
    PubMed    
    Abstract available

  139. JIANG S, Gai X, Mao T, Yu H, et al
    Associations of APE1 and OGG1 polymorphisms with onset and prognosis of bladder cancer.
    Panminerva Med. 2021 Jan 20. pii: S0031-0808.20.04245.
    PubMed    


  140. CHEN D, Chen T, Guo Y, Wang C, et al
    Suppressive effect of platycodin D on bladder cancer through microRNA-129-5p-mediated PABPC1/PI3K/AKT axis inactivation.
    Braz J Med Biol Res. 2021;54:e10222.
    PubMed    
    Abstract available

  141. HUANG X, Zhou Q, Wang M, Cao C, et al
    A Light-Inducible Split-dCas9 System for Inhibiting the Progression of Bladder Cancer Cells by Activating p53 and E-cadherin.
    Front Mol Biosci. 2021;7:627848.
    PubMed    
    Abstract available

  142. OKAZAKI N, Kasahara K, Watanabe M, Wada T, et al
    [A Case of Colorectal Cancer with Bladder Invasion Treated Ileal Neobladder for Urinary Bladder Replacement].
    Gan To Kagaku Ryoho. 2020;47:2074-2076.
    PubMed    
    Abstract available

  143. TAUBERT H, Eckstein M, Epple E, Jung R, et al
    Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
    Cells. 2021;10.
    PubMed    
    Abstract available

  144. SCHOLTES MP, de Jong FC, Zuiverloon TCM, Theodorescu D, et al
    Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  145. JIN K, Qiu S, Jin D, Zhou X, et al
    Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database.
    Aging (Albany NY). 2021;12.
    PubMed    
    Abstract available

  146. TIAN J, Hu P, Guo H, Xu J, et al
    Effect of transurethral partial cystectomy with 2.0 mum laser in treating superficial bladder cancer.
    J BUON. 2020;25:2714-2720.
    PubMed    
    Abstract available

  147. TELEKA S, Jochems SHJ, Haggstrom C, Wood AM, et al
    Association between blood pressure and BMI with bladder cancer risk and mortality in 340,000 men in three Swedish cohorts.
    Cancer Med. 2021 Jan 16. doi: 10.1002/cam4.3721.
    PubMed    
    Abstract available

  148. SONG W, Yang K, Luo J, Gao Z, et al
    Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression.
    Aging (Albany NY). 2021;12.
    PubMed    
    Abstract available

  149. SHEN C, Wang L, Yang X, Liu J, et al
    Construction of a immune-associated genes based prognostic signature in bladder cancer.
    Artif Cells Nanomed Biotechnol. 2021;49:108-119.
    PubMed    
    Abstract available

  150. PACKIAM VT, Tsivian M, Boorjian SA
    The evolving role of lymphadenectomy for bladder cancer: why, when, and how.
    Transl Androl Urol. 2020;9:3082-3093.
    PubMed    
    Abstract available

  151. SUNG LH, Yuk HD
    Enhanced recovery after surgery of patients undergoing radical cystectomy for bladder cancer.
    Transl Androl Urol. 2020;9:2986-2996.
    PubMed    
    Abstract available

  152. KIM IH, Lee HJ
    Perioperative immunotherapy for muscle-invasive bladder cancer.
    Transl Androl Urol. 2020;9:2976-2985.
    PubMed    
    Abstract available

  153. TIWARI RV, Ngo NT, Lee LS
    The optimal management of variant histology in muscle invasive bladder cancer.
    Transl Androl Urol. 2020;9:2965-2975.
    PubMed    
    Abstract available

  154. CLINTON TN, Huang C, Goh AC
    Is there an oncological benefit to extended lymphadenectomy for muscle-invasive bladder cancer?
    Transl Androl Urol. 2020;9:2956-2964.
    PubMed    
    Abstract available

  155. BRODIE A, Kijvikai K, Decaestecker K, Vasdev N, et al
    Review of the evidence for robotic-assisted robotic cystectomy and intra-corporeal urinary diversion in bladder cancer.
    Transl Androl Urol. 2020;9:2946-2955.
    PubMed    
    Abstract available

  156. PEAK TC, Hemal A
    Partial cystectomy for muscle-invasive bladder cancer: a review of the literature.
    Transl Androl Urol. 2020;9:2938-2945.
    PubMed    
    Abstract available

  157. THOLOMIER C, Souhami L, Kassouf W
    Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer.
    Transl Androl Urol. 2020;9:2920-2937.
    PubMed    
    Abstract available

  158. KIM SK
    Role of PET/CT in muscle-invasive bladder cancer.
    Transl Androl Urol. 2020;9:2908-2919.
    PubMed    
    Abstract available

  159. SIM KC, Sung DJ
    Role of magnetic resonance imaging in tumor staging and follow-up for bladder cancer.
    Transl Androl Urol. 2020;9:2890-2907.
    PubMed    
    Abstract available

  160. FONG MHY, Feng M, McConkey DJ, Choi W, et al
    Update on bladder cancer molecular subtypes.
    Transl Androl Urol. 2020;9:2881-2889.
    PubMed    
    Abstract available

  161. KANG HW, Kim WJ, Choi W, Yun SJ, et al
    Tumor heterogeneity in muscle-invasive bladder cancer.
    Transl Androl Urol. 2020;9:2866-2880.
    PubMed    
    Abstract available

  162. KU JH, Seo HK, Kang SH
    Where are we now and where are we heading in muscle invasive bladder cancer.
    Transl Androl Urol. 2020;9:2864-2865.
    PubMed    


  163. PACKIAM VT
    Consensus statements from the EAU-ESMO collaboration for advanced and variant bladder cancer: can we move the needle to improve survival?
    Transl Androl Urol. 2020;9:2488-2492.
    PubMed    


  164. POLETAJEW S, Krajewski W, Kryst P
    Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?
    Transl Androl Urol. 2020;9:2479-2482.
    PubMed    


  165. WONG BS, Duran C, Williams SB
    Vesical imaging reporting and data system (VI-RADS) and impact on identifying depth of invasion with subsequent management in bladder cancer patients: ready for prime time?
    Transl Androl Urol. 2020;9:2467-2470.
    PubMed    


  166. ZHOU Q, Wang Z, Zeng H, Zhang H, et al
    Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin(+) cell abundance.
    Oncoimmunology. 2020;9:1747333.
    PubMed    
    Abstract available

  167. GILL HS, Dasari SP, Pandit S, Ritter TE, et al
    Disseminated M. bovis Infection and Vertebral Osteomyelitis following Immunotherapy for Bladder Cancer.
    Case Rep Infect Dis. 2020;2020:6676163.
    PubMed    
    Abstract available

  168. SHEN C, Xu T, Sun Y, Wang L, et al
    Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer.
    Dis Markers. 2020;2020:8866730.
    PubMed    
    Abstract available

  169. REY-CARDENAS M, Guerrero-Ramos F, Gomez de Liano Lista A, Carretero-Gonzalez A, et al
    Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future.
    Cancer Treat Rev. 2021;93:102142.
    PubMed    
    Abstract available

  170. ZHANG X, Zhang J, Zhang H, Liu Y, et al
    Exploring the five different genes associated with PKCalpha in bladder cancer based on gene expression microarray.
    J Cell Mol Med. 2021 Jan 15. doi: 10.1111/jcmm.16284.
    PubMed    
    Abstract available

  171. CHANG NT, Chang YH, Huang YT, Chen SC, et al
    Factors Associated with Refusal or Discontinuation of Treatment in Patients with Bladder Cancer: A Cohort Population-Based Study in Taiwan.
    Int J Environ Res Public Health. 2021;18.
    PubMed    
    Abstract available

  172. KADOURI Y, Boualaoui I, Lachkar S, Sayegh HE, et al
    [Squamous cell carcinoma of the bladder: a retrospective study conducted in a Moroccan University Hospital and literature review].
    Pan Afr Med J. 2020;37:143.
    PubMed    
    Abstract available

  173. PARK JY, Hong JH, Kim DH, Yu J, et al
    Magnesium and Bladder Discomfort after Transurethral Resection of Bladder Tumor.
    Anesthesiology. 2020;133:64-77.
    PubMed    
    Abstract available

  174. DAVIDSON PJ, McGeoch G, Shand B
    Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy.
    N Z Med J. 2020;133:71-82.
    PubMed    
    Abstract available

  175. LOUREIRO LR, Feldmann A, Bergmann R, Koristka S, et al
    Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.
    J Exp Clin Cancer Res. 2020;39:77.
    PubMed    
    Abstract available

  176. BOGDAN RUSU C, Bujoreanu CE, Irimie A, Achimas-Cadariu P, et al
    Totally intracorporeal 3D laparoscopic orthotopic neobladder reconstruction following radical cystectomy for infiltrative bladder tumors: the experience of modified Studer and modified Y-shaped ileal reconstruction techniques.
    J BUON. 2020;25:286-294.
    PubMed    
    Abstract available

  177. CHAE HK, Yang JI, An JH, Lee IH, et al
    Use of oral paclitaxel for the treatment of bladder tumors in dogs.
    J Vet Med Sci. 2020;82:527-530.
    PubMed    
    Abstract available

  178. GORET CC
    Neuroendocrine tumors of the urinary bladder A case series and review of the literature.
    Ann Ital Chir. 2020;91:65-68.
    PubMed    
    Abstract available

  179. LIU Y, Ilyas M, Khosa SK, Muhmoudi E, et al
    A Flexible Reduced Logarithmic-X Family of Distributions with Biomedical Analysis.
    Comput Math Methods Med. 2020;2020:4373595.
    PubMed    
    Abstract available

  180. CHEN Z, Yang L, Chen L, Li J, et al
    miR-190b promotes tumor growth and metastasis via suppressing NLRC3 in bladder carcinoma.
    FASEB J. 2020;34:4072-4084.
    PubMed    
    Abstract available

  181. HAMZA A, Guo CC
    Perivascular Epithelioid Cell Tumor of the Urinary Bladder: A Systematic Review.
    Int J Surg Pathol. 2020;28:393-400.
    PubMed    
    Abstract available

  182. RICHTERS A, Ripping TM, Kiemeney LA, Leliveld AM, et al
    Hospital volume is associated with postoperative mortality following radical cystectomy for treatment of bladder cancer.
    BJU Int. 2021 Jan 6. doi: 10.1111/bju.15334.
    PubMed    
    Abstract available

  183. DUNSMORE J, Duncan E, Mariappan P, de Bruin M, et al
    What influences adherence to guidance for post-operative instillation of intravesical chemotherapy to bladder cancer patients?
    BJU Int. 2021 Jan 15. doi: 10.1111/bju.15336.
    PubMed    
    Abstract available

  184. VAN DER VLIES E, Los M, Stijns PEF, van Hengel M, et al
    Preoperative frailty and outcome in patients undergoing radical cystectomy.
    BJU Int. 2020;126:388-395.
    PubMed    
    Abstract available

  185. BREE KK, Hensley PJ, Brooks NA, Matulay J, et al
    Impact of upper tract urothelial carcinoma on response to bcg in patients with non-muscle invasive bladder cancer.
    BJU Int. 2021 Jan 22. doi: 10.1111/bju.15344.
    PubMed    
    Abstract available

  186. HOSSEINI A, Mortezavi A, Sjoberg S, Laurin O, et al
    Robot-assisted intracorporeal orthotopic bladder substitution after radical cystectomy: perioperative morbidity and oncological outcomes - a single-institution experience.
    BJU Int. 2020;126:464-471.
    PubMed    
    Abstract available

  187. PAL SK, Bajorin D, Dizman N, Hoffman-Censits J, et al
    Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
    Cancer. 2020;126:2597-2606.
    PubMed    
    Abstract available

  188. HUGAR LA, Gilbert SM, Sexton WJ, Kamat AM, et al
    Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2020;Publish Ahead of Print.
    PubMed    
    Abstract available

  189. GIANNARINI G, Valotto C, Ficarra V
    Re: Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-institutional Randomized Trial Comparing Robot Versus Open Radical Cystectomy.
    Eur Urol. 2020 Dec 19. pii: S0302-2838(20)30954.
    PubMed    


  190. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
    European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31019.
    PubMed    
    Abstract available

  191. PERERA-BEL J, Bellmunt J
    Reply to Anirban P. Mitra, Tanner Miest, and Colin P.N. Dinney's Words of Wisdom re: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.euru
    Eur Urol. 2021 Jan 5. pii: S0302-2838(20)31024.
    PubMed    


  192. WIJBURG CJ, Michels CTJ, Grutters JPC, Rovers MM, et al
    Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Bladder Cancer Patients: A Multicentre Comparative Effectiveness Study.
    Eur Urol. 2021 Jan 11. pii: S0302-2838(20)31009.
    PubMed    
    Abstract available

  193. LI R, Lerner SP, Kamat AM
    The Who, What, When, Where, and Why of Bacillus Calmette-Guerin-unresponsive Bladder Cancer.
    Eur Urol. 2021 Jan 13. pii: S0302-2838(21)00001.
    PubMed    
    Abstract available

  194. SHAH A, Tan WP, Inman BA
    National Quality Improvement Program in Transurethral Resection of Bladder Tumor: A Model for the Rest of Us, Even if We Cannot Share All Results.
    Eur Urol. 2020;78:531-532.
    PubMed    


  195. GRIMBERG DC, Shah A, Inman BA
    En Bloc Resection of Bladder Tumors: Style or Substance?
    Eur Urol. 2020;78:570-571.
    PubMed    


  196. XU T, Li HT, Wei J, Li M, et al
    Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype.
    Int J Cancer. 2020;146:3065-3076.
    PubMed    
    Abstract available

  197. YASUI M, Ohta JI, Aoki S, Tajirika H, et al
    Prognosis of patients with T1 bladder cancer after en bloc transurethral resection of bladder tumor stratified by invasion to the level of the muscularis mucosa.
    Int Urol Nephrol. 2021 Jan 2. pii: 10.1007/s11255-020-02772.
    PubMed    
    Abstract available

  198. FARAJ KS, Navaratnam AK, Eversman S, Elias L, et al
    Use of treatment pathway improves neoadjuvant chemotherapy use in muscle-invasive bladder cancer.
    Int Urol Nephrol. 2021 Jan 3. pii: 10.1007/s11255-020-02752.
    PubMed    
    Abstract available

  199. PETRUZELLA S, Bochner BH, Kenney J, Whiting K, et al
    Examining the Accuracy of Self-Reported Smoking-Related Exposure Among Recently Diagnosed Non-muscle Invasive Bladder Cancer Patients.
    J Urol. 2020 Dec 24:101097JU0000000000001571. doi: 10.1097/JU.0000000000001571.
    PubMed    
    Abstract available

  200. KIRSCHNER AN, Wang J, Rajkumar-Calkins A, Neuzil KE, et al
    Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.
    J Urol. 2020 Dec 24:101097JU0000000000001576. doi: 10.1097/JU.0000000000001576.
    PubMed    
    Abstract available

  201. XIONG Y, Ju L, Yuan L, Chen L, et al
    KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.
    Oncogene. 2021 Jan 15. pii: 10.1038/s41388-020-01634.
    PubMed    
    Abstract available

  202. PIGNOT G, Sargos P
    [Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer].
    Prog Urol. 2020 Dec 23. pii: S1166-7087(20)30741.
    PubMed    
    Abstract available

  203. SUCH M, Lavolle A, Popelin MB, Thibault C, et al
    Administration of neoadjuvant chemotherapy for muscle-invasive bladder cancer in real life: Are urologists still too cautious?
    Prog Urol. 2021 Jan 16. pii: S1166-7087(20)30742.
    PubMed    
    Abstract available

  204. NYAME YA, Holt SK, Diamontopolous L, Winters BR, et al
    Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries with Muscle Invasive Bladder Cancer from 2004-2015.
    Urology. 2020 Dec 26. pii: S0090-4295(20)31518.
    PubMed    
    Abstract available

  205. BASSETT JC, Matulewicz RS, Kwan L, McCarthy WJ, et al
    Prevalence and Correlates of Successful Smoking Cessation in Bladder Cancer Survivors.
    Urology. 2021 Jan 12. pii: S0090-4295(21)00047.
    PubMed    
    Abstract available

  206. PORRECA A, Palmer K, Artibani W, Antonelli A, et al
    Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer.
    BMC Cancer. 2021;21:51.
    PubMed    
    Abstract available

  207. OKAMURA S, Yoshino H, Kuroshima K, Tsuruda M, et al
    EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer.
    BMC Cancer. 2021;21:48.
    PubMed    
    Abstract available

  208. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;